Trial | NCT02145065  Report issue

Title

First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
Prospective, Pivotal, First - in Man Clinical Trial of the Safety and Efficacy of a Novel Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    paclitaxel ...

  • Study Participants

    66
The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.
Although clinically effective, the manufacturing process of first generation PCB coatings contributed to inconsistent drug concentrations, particulate formations on the balloon surface and their shedding during the interventional procedures. As a consequence developments of new PCB coatings have been proposed to address consistency, uniformity, small particle drug coverage, which may potentially contribute to improved vessel healing profile and improved clinical outcomes. Nevertheless, data on the safety and efficacy of this novel coating developments in the clinical setting remain limited. Previously in the experimental model, the investigators reported that delivery of paclitaxel via a novel mcPCB resulted in low long-term tissue retention of paclitaxel, however displayed reduced neointimal proliferation and favorable healing profile. Therefore in current clinical trial the investigators will address the feasibility and safety of the mcPCB (PAK, Balton) in the treatment of femoropopliteal restenotic disease in a prospective, randomized manner when compared to plain balloon angioplasty (PBA). The efficacy analysis will be observational and evaluated post-hoc, with no prespecified criteria.
Study Started
Sep 30
2014
Primary Completion
Sep 30
2017
Study Completion
Oct 31
2017
Last Update
Aug 07
2018

Drug Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)

Device Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)

Plain Balloon Angioplasty Active Comparator

Plain Balloon Angioplasty

microcrystalline Paclitaxel Coated Balloon (PAK) Experimental

plain balloon angioplasty followed by mcPCB dilation

Criteria 

Inclusion Criteria:

Age > 18 y.o.
Claudication in Rutherford Class 1-5,
Lesion in the femoropopliteal artery defined as >50% and < 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm
Chronic total occlusions of length less than 100 mm
Ability to cross the lesions with a guidewire.

Exclusion Criteria:

Critical acute or chronic limb ischemia
Acute coronary syndrome
Chronic kidney disease stage III-V
Restenotic lesion
Femoropopliteal graft
Known allergy to clopidogrel or aspirin
History of stroke within past 6 months
Age > 80 y.o.
Life expectancy < 2 years
No Results Posted